NFE2L2 and diabetic cardiomyopathy: Moreover, NRF2 has been suggested as a therapeutic target for lung oxidative injuries, cancer, Alzheimer’s disease, and diabetic cardiomyopathy (Lu et al., 2016; Dianat et al., 2018; Bahn and Jo, 2019; Ge et al., 2019).